NF-κB/IκB

TIC10g is a dual inhibitor of toll-like receptors 7 and 9 (TLR7 and TLR9). It effectively decreases TNF-α release in mouse macrophages and human B lymphocytes, with IC50 values of 14.5 μM and 6.5 μM for TLR7, and 7.69 μM and 11.5 μM for TLR9, respectively. TIC10g also inhibits the activation of NF-κB and MAPK pathways, demonstrating potential as an anti-inflammatory agent in conditions such as systemic lupus erythematosus and rheumatoid arthritis.

NCI126224 is a TLR4 signaling inhibitor that modulates immune responses by suppressing lipopolysaccharide (LPS)-induced production of key inflammatory mediators, including NF-κB, TNF-α, IL-1β, and nitric oxide. This compound demonstrates biological activity in the low nanomolar to low micromolar range, making it a valuable tool for research into inflammatory diseases and their mechanisms. Its ability to interfere with TLR4 signaling pathways positions NCI126224 as a significant reagent for exploring potential therapeutic strategies in inflammation-related studies.

TLR4/NF-κB/MAPK-IN-1 is an inhibitor targeting the TLR4/NF-κB/MAPK signaling pathways. It exhibits significant anti-neuroinflammatory activity by suppressing the activation of these pathways, leading to reduced inflammatory responses. This compound is particularly useful for research applications focusing on neuroinflammation and related neurodegenerative diseases.

Ligusticum cycloprolactam is a potent TLR4/NF-κB inhibitor with significant anti-inflammatory properties. It has been shown to alleviate renal injury by effectively disrupting the TLR4/NF-κB signaling pathway in both in vivo and in vitro models. In studies, Ligusticum cycloprolactam reduces serum uric acid levels, diminishes tubular damage, and decreases inflammatory infiltration and interstitial collagen deposition, leading to improved renal function. This compound serves as a valuable reagent for research into hyperuricemic nephropathy.

NF-κB-IN-14 is an NF-κB inhibitor that effectively modulates inflammatory responses by significantly inhibiting nitric oxide production in LPS-stimulated macrophages, with an IC50 of 6.4 μM. This compound disrupts the TLR4-MyD88 protein interaction, leading to the suppression of the NF-κB signaling pathway. Additionally, NF-κB-IN-14 has demonstrated efficacy in reducing ear edema and inflammation in a mouse model of atopic dermatitis, highlighting its potential utility in inflammatory research.

LM9 is a selective inhibitor of MyD88, a key adaptor protein in the Toll-like receptor (TLR) signaling pathway. By blocking the binding of TLR4 to MyD88, LM9 disrupts MyD88 homodimer formation and subsequent activation of the NF-κB signaling pathway. This compound demonstrates significant anti-inflammatory effects, mitigating atherosclerosis and fibrosis in models of obesity-induced cardiomyopathy. LM9 is valuable for research focused on understanding the mechanisms of inflammation, fibrosis, and cardiovascular diseases.

TLR4-IN-2 is an inhibitor targeting TLR4, JNK, and NF-κB pathways. It demonstrates anti-inflammatory properties by reducing nitric oxide production in LPS-stimulated RAW264.7 cells, with an IC50 of 23.2 µM. By inhibiting TLR4 expression and diminishing JNK phosphorylation, TLR4-IN-2 effectively suppresses NF-κB activation and the transcription of inflammation-related genes, leading to lower levels of iNOS, COX-2, and various inflammatory mediators. This compound shows potential for investigating therapeutic strategies in inflammatory diseases such as rheumatoid arthritis and other inflammatory disorders.

Ergolide is a selective NF-κB/p65 and NLRP3 inhibitor that effectively disrupts the NF-κB signaling pathway and inhibits the nuclear translocation of p65. By irreversibly binding to the NACHT domain of NLRP3, Ergolie suppresses inflammasome assembly, significantly reducing the production of inflammatory mediators such as NO and PGE2. This compound promotes apoptosis in cancer cells, induces autophagy, and generates reactive oxygen species (ROS). Ergolide also enhances the therapeutic efficacy of vincristine and has been shown to alleviate acute lung injury in models of sepsis and inflammation, contributing to research in metastatic uveal melanoma, neurodegenerative diseases, and acute lymphoblastic leukemia.

NF-κB/PON1-IN-1 is an NF-κB/PON1 pathway inhibitor that exhibits pronounced antioxidant properties with an IC50 of 45.76 µM. This compound demonstrates hepatoprotective activity, making it valuable for research focused on inflammation and oxidative stress. Its mechanism of action positions it as a potential therapeutic tool in studies investigating liver-related diseases and cellular protection.

RANKL-IN-2 is a selective inhibitor of RANKL, exhibiting Kd values of 3.21 μM and 4.625 μM in surface plasmon resonance and microscale thermophoresis assays, respectively. By binding to RANKL, it disrupts the RANKL-RANK interaction, thereby suppressing osteoclastogenesis through the inhibition of reactive oxygen species, MAPK, and NF-κB signaling pathways. RANKL-IN-2 demonstrates efficacy in preventing RANKL-induced osteoclast formation, bone resorption, and the expression of osteoclast-specific genes and proteins in vitro. Additionally, RANKL-IN-2 has shown potential in preventing bone loss in ovariectomized mouse models, making it a valuable tool for osteoporosis research.

Pteryxin is a potent butyrylcholinesterase (BChE) inhibitor (IC50 = 12.96 μg/mL) with additional multi-target mechanisms including inhibition of NF-κB, MAPK, NLRP3 inflammasome activation, and modulation of the Nrf2/ARE pathways. This compound demonstrates significant anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin is suitable for research applications related to inflammatory diseases, osteoporosis, diabetes, and neurodegenerative disorders such as Alzheimer's disease.

Anemoside A3-methyl 6-aminohexanoate is a potent pyruvate carboxylase (PC) inhibitor, exhibiting a Kd value of 10.1 μM against human PC. This compound influences cellular pathways through the PC/NF-κB/NLRP3 inflammasome axis, demonstrating significant efficacy in alleviating symptoms of DSS-induced colitis in murine models. Anemoside A3-methyl 6-aminohexanoate serves as a useful tool in colitis-related research and studies focusing on the modulation of inflammatory pathways.

Yadanzigan is a potent NLRP3 inhibitor that exerts its anti-inflammatory effects by inhibiting the NF-κB signaling pathway and reducing Reactive Oxygen Species production. This compound has been shown to mitigate LPS-induced acute lung injury (ALI) in murine models, highlighting its potential for research in inflammation-related conditions. Its mechanism of action positions Yadanzigan as a valuable tool for studying NLRP3-related pathways and their roles in various pathological processes.

Articaine is a selective inhibitor of voltage-gated sodium channels, including rNav1.4, hNav1.7, and rNav1.8, demonstrating an IC50 of 15.8 μM for open-state Na+ channels. It effectively blocks Na+ influx, leading to local anesthetic effects and interruption of nerve impulse conduction. Additionally, Articaine exhibits anti-inflammatory properties by inhibiting NF-κB activation and the NLRP3 inflammasome pathway. This compound is valuable for research in dental anesthesia and inflammatory-related conditions, such as acute kidney injury.

NLRP3-IN-69 is a selective inhibitor of the NLRP3 inflammasome, targeting the activation of NF-κB p65. This compound effectively reduces LPS-induced overexpression of pro-inflammatory cytokines including IL-1β, as well as iNOS and COX-2, while inhibiting nitric oxide generation with an IC50 of 5.66 μM. NLRP3-IN-69 serves as a valuable tool in research focused on inflammatory diseases and the modulation of the immune response.

COX-2/NLRP3-IN-1 is a selective inhibitor targeting both COX-2 and the NLRP3 inflammasome, with an IC50 of 1.53 μM for COX-2. This compound exhibits notable anti-inflammatory properties by disrupting the NF-κB/NLRP3 signaling pathway, making it a valuable tool for research into inflammatory diseases. It is suitable for studying the roles of COX-2 and NLRP3 in various biological processes and therapeutic interventions.

1-Caffeoylquinic acid is a potent inhibitor of NF-κB, demonstrating a significant binding affinity to the RH domain of p105 with a Ki value of 0.007 μM. This compound exhibits notable anti-oxidative stress properties and serves as an inhibitor for the PD-1/PD-L1 pathway. Its biological activities make it valuable for research applications in inflammation, immunity, and cancer studies.

K284-6111 is a potent inhibitor of CHI3L1, demonstrating high affinity and oral bioavailability. It effectively suppresses CHI3L1 expression and disrupts key signaling pathways, including ERK and NF-κB, leading to reduced nuclear translocation of p50 and p65 as well as decreased phosphorylation of IκB. K284-6111 shows promise in alleviating memory dysfunction associated with Alzheimer's disease by mitigating amyloidogenesis and neuroinflammation. Additionally, it exhibits therapeutic potential in reducing atopic-like skin inflammation and protecting against LPS-induced liver injury. This compound is suitable for research into neurodegenerative diseases and inflammatory conditions.

Valencene is a sesquiterpene that functions as an NF-κB inhibitor. It exhibits significant anti-inflammatory, antiallergic, and antioxidant activities by inhibiting the expression of Th2 chemokines and proinflammatory cytokines. In LPS-stimulated RAW 264.7 cells, Valencene effectively reduces the production of IL-1β and IL-6. Additionally, Valencene has demonstrated potential in alleviating symptoms of atopic dermatitis and restoring filaggrin expression in a DNCB-sensitized mouse model.

Dimethyl diacetyl cystinate (DACDM) is a potent NF-κB inhibitor that modulates inflammation by shifting the intracellular redox balance towards an oxidized state. This compound increases the levels of oxidized glutathione (GSSG) and competes with activated NF-κB for binding sites on DNA, thus inhibiting the production of pro-inflammatory cytokines such as IL-1κ. DACDM is a valuable reagent for studies related to UVB-induced skin inflammation and various oxidative stress-related diseases.

β-Glucogallin is a selective inhibitor of aldose reductase (AKR1B1), exhibiting an IC50 value of 58 μM with glyceraldehyde as the substrate. This compound displays significant antioxidant properties, reducing reactive oxygen species (ROS) and influencing key pathways involving PDGF, RAGE, and NF-κB. Additionally, β-Glucogallin enhances superoxide dismutase (SOD) activity and demonstrates hepatoprotective effects. Its biological activity makes it a valuable tool for research in retinal studies and related fields.

XRF-1021 is an orally active inhibitor of Homer-interacting protein kinase 2 (HIPK2), with an IC50 value of 0.18 μM. It effectively decreases the expression of fibrotic markers such as Fibronectin, Collagen I, and α-SMA in TGF-β1 stimulated renal cell lines, including NRK-49F and HK-2. XRF-1021 further inhibits key signaling pathways including TGF-β, NF-κB, p53, Wnt/β-catenin, and Notch. This compound demonstrates potential in reducing renal injury and fibrosis in vivo, making it a valuable tool for research on chronic kidney disease.

Okanin is a potent Toll-like Receptor (TLR) inhibitor derived from the flowering plant Coreopsis tinctoria. It exhibits significant biological activity by attenuating lipopolysaccharide (LPS)-induced microglial activation via the inhibition of the TLR4/NF-κB signaling pathway. This compound is useful for research applications focusing on neuroinflammation and the modulation of immune responses in microglial cells.

(Rac)-AAA is a potent inhibitor of GPR75, targeting the receptor to modulate key signaling pathways. This compound effectively blocks the downregulation of GPR75 expression induced by 20-HETE, leading to the inhibition of downstream pathways such as EGFR, AKT, NF-κB, and FAK. (Rac)-AAA also reverses 20-HETE-mediated epithelial-mesenchymal transition, characterized by the downregulation of vimentin and upregulation of E-Cadherin, while reducing MMP-2 activity and cancer cell migration. Additionally, it mitigates the upregulation of HIC-5 and affects the localization of PKC-α and phosphorylated AKT, making (Rac)-AAA a significant tool in the study of castration-resistant prostate cancer.

MY10 is a potent inhibitor of receptor protein tyrosine phosphatase β/ζ (RPTPβ/ζ) that exhibits oral bioactivity. It has been shown to reduce NF-κB p65 expression and activate c-Met tyrosine phosphorylation. Additionally, MY10 prevents the alcohol-induced downregulation of Ptprz1 and Alk expression, while attenuating binge-like ethanol consumption and associated rewards. This compound is valuable for investigating neurological and vascular diseases.

Gabexate mesylate is a competitive proteasome inhibitor, primarily targeting serine proteinases such as thrombin and Factor Xa. It exhibits diverse biological activity, including anticoagulant effects by modulating thrombin activity and anti-inflammatory properties through the inhibition of NF-κB and proinflammatory cytokines. Gabexate mesylate is commonly utilized in research focused on pancreatitis and disseminated intravascular coagulation, making it a valuable reagent for studies in hemostasis and inflammation.

Erdosteine functions as a bacterial inhibitor by inhibiting lipopolysaccharide (LPS)-induced activation of NF-κB. This compound exhibits muco-modulatory, anti-bacterial, anti-inflammatory, and antioxidant properties. Erdosteine is primarily utilized in research applications focused on respiratory disorders and inflammation, supporting the study of therapeutic interventions in these areas.

Isoquercitrin is a potent nitric oxide synthase inhibitor with significant antioxidant and anti-inflammatory properties. This naturally occurring polyphenol exerts protective effects against ethanol-induced hepatotoxicity and oxidative stress, primarily through the activation of the Nrf2/ARE signaling pathway. Additionally, Isoquercitrin modulates the expression of nitric oxide synthase 2 (NOS2) via the nuclear factor-κB (NF-κB) regulatory mechanism. Due to its high bioavailability and low toxicity, Isoquercitrin presents potential applications in research on metabolic disorders and the prevention of birth defects in diabetic pregnancies.

Benzoyloxypaeoniflorin is a potent tyrosinase inhibitor derived from the root of Paeonia suffruticosa, exhibiting an IC50 value of 0.453 mM against mushroom tyrosinase. Additionally, it functions as an NF-κB inhibitor, contributing to enhanced blood circulation by inhibiting platelet aggregation and blood coagulation. This compound is of significant interest in research applications focused on skin disorders and inflammation.

Flaconitine is a potent inhibitor of the NF-κB signaling pathway. This compound has been shown to effectively block the activation of NF-κB, thus modulating inflammatory responses. Flaconitine is widely used in research focused on immunology, cancer biology, and studies involving inflammatory diseases. Its ability to regulate gene expression through NF-κB inhibition makes it a valuable tool for investigating cellular signaling and therapeutic pathways.

Tolterodine is an mAChR inhibitor that competitively binds to acetylcholine, leading to a reduction in sympathetic excitation and inhibition of involuntary bladder muscle contractions. It is known to restore the Nrf2/NF-κB signaling pathway, providing protection against inflammatory responses and ferroptosis. Additionally, Tolterodine mitigates LPS-induced reactive oxygen species production and lipid oxidation, making it valuable for research in urinary tract infections and overactive bladder conditions.

RN-0001 is a potent inhibitor of cyclophilins, specifically demonstrating Ki values of 4.1 nM and 12.0 nM against Cyclophilin A (CypA) and Cyclophilin D (CypD), respectively. By directly binding to CypD, RN-0001 effectively inhibits its peptidyl-prolyl cis-trans isomerase activity, preventing mitochondrial permeability transition pore opening. This compound enhances mitochondrial function, diminishes reactive oxygen species (ROS) production, and downregulates lipogenic marker expression. Additionally, RN-0001 inhibits NF-κB p65 nuclear translocation and reduces the release of activated caspase-3 and cytochrome c, making it a valuable tool for investigating alcohol-associated liver disease.

HDAC2-IN-3 is a selective HDAC2 inhibitor with an IC50 of 14 nM, capable of crossing the blood-brain barrier. This compound effectively upregulates histone acetylation levels both in cultured cells and in vivo, and has been shown to enhance long-term potentiation (LTP) in the hippocampus. HDAC2-IN-3 is valuable for research applications focused on neurodegenerative disorders, particularly Alzheimer's disease.

HDAC8-IN-16 is a selective inhibitor of histone deacetylase 8 (HDAC8), exhibiting an IC50 of 0.16 μM. It has been shown to induce apoptosis in various cell lines, trigger G2/M phase cell cycle arrest, and moderately inhibit cancer cell proliferation. This compound is particularly relevant for research applications related to colorectal cancer, providing valuable insights into the therapeutic potential of HDAC8 modulation.

HDAC6-IN-78 is a highly selective inhibitor of histone deacetylase 6 (HDAC6), exhibiting an IC50 of 24 nM. This compound demonstrates specificity by showing no significant activity against other HDAC isoforms. HDAC6-IN-78 is valuable for research applications focused on studying the role of HDAC6 in cellular processes, including neurodegenerative diseases and cancer.

NCT-10b is a selective inhibitor of HDAC6, primarily targeting this enzyme to influence cellular processes. It facilitates α-tubulin acetylation while having minimal effect on histone H4 acetylation. NCT-10b is applicable in research focused on multiple myeloma, providing insights into the mechanisms of this hematological malignancy and potential therapeutic strategies.

Rhynchophylline is an alkaloid compound characterized as an NF-κB inhibitor. It exhibits significant biological activity with potential applications in anti-inflammatory and neuroprotective research. This compound is derived from Uncaria rhynchophyllum and is of interest for studies investigating the modulation of inflammatory pathways and neuronal protection mechanisms.